Matias, Jaqueline
Cui, Yingjun
Lynn, Geoffrey E.
DePonte, Kathleen
Mesquita, Emily
Muramatsu, Hiromi
Alameh, Mohamad G.
Dwivedi, Garima
Tam, Ying K.
Pardi, Norbert
Weissman, Drew
Fikrig, Erol
Funding for this research was provided by:
National Institutes of Health (AI165499)
Howard Hughes Medical Institute
Steven and Alexandra Cohen Foundation
Article History
Received: 29 September 2023
Accepted: 19 December 2023
First Online: 4 January 2024
Competing interests
: N.P. and D.W. are named on a patent describing the use of nucleoside-modified mRNA in lipid nanoparticles as a vaccine platform. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. N.P. served on the mRNA strategic advisory board of Sanofi Pasteur in 2022. N.P. is a member of the scientific advisory board of AldexChem.